Cancer incidence in pulmonary vasculitis

Area of Science:

• Immunology
• Oncology
• Rheumatology

Background:

• Pulmonary vasculitis is a severe autoimmune condition requiring immunosuppressive therapy.
• Cyclophosphamide, a common treatment, carries risks of secondary malignancies due to its toxic metabolite, acrolein.
• High relapse rates necessitate prolonged cyclophosphamide use in some patients.

Purpose of the Study:

• To evaluate cancer incidence in pulmonary vasculitis patients compared to the general population.
• To analyze cancer risk based on cumulative cyclophosphamide dosage.
• To highlight the importance of long-term monitoring for malignancies.

Main Methods:

• Retrospective analysis of cancer incidence in pulmonary vasculitis patients.
• Comparison with general population cancer rates.
• Stratification of patients by cumulative cyclophosphamide dose (low: ≤35 g, high: >35 g).

Main Results:

• A significantly increased standardized incidence ratio (SIR) was found for non-melanoma skin cancers (SIR 5.2), acute myeloid leukemia (AML) (SIR 4.3), and bladder cancer (SIR 3.4).
• Cancer occurrence was dose-dependent on cyclophosphamide.
• Fifteen cancers were observed during the study period.

Conclusions:

• Cyclophosphamide treatment for pulmonary vasculitis substantially increases the risk of developing various cancers, including AML and bladder cancer.
• The risk of these late-appearing malignancies is linked to the cumulative dose of cyclophosphamide.
• Post-treatment monitoring and prophylactic strategies are crucial for managing these risks in pulmonary vasculitis patients.